Literature DB >> 10388480

Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study.

L J Seman1, C DeLuca, J L Jenner, L A Cupples, J R McNamara, P W Wilson, W P Castelli, J M Ordovas, E J Schaefer.   

Abstract

BACKGROUND: Increased plasma lipoprotein(a) [Lp(a)] concentrations have been reported to be an independent risk factor for coronary heart disease (CHD) in some prospective studies, but not in others. These inconsistencies may relate to a lack of standardization and the failure of some immunoassays to measure all apolipoprotein(a) isoforms equally.
METHODS: We measured plasma Lp(a)-cholesterol [Lp(a)-C] in a Caucasian population of offspring and spouses of the Framingham Heart Study participants, using a lectin-based assay (LipoproTM). We compared the prevalence of increased Lp(a)-C to the presence of sinking pre-beta-lipoprotein (SPB). We also related Lp(a)-C concentrations to the prevalence of CHD risk in the entire population.
RESULTS: The mean (+/- SD) Lp(a)-C concentration in the Framingham population (n = 3121) was 0.186 +/- 0.160 mmol/L, with no significant gender or age differences. The mean Lp(a)-C concentrations in the absence or presence of SPB were 0.158 +/- 0. 132 mmol/L and 0.453 +/- 0.220 mmol/L, respectively (P <0.0001). The mean Lp(a)-C concentration in men with CHD (n = 156) was 0.241 +/- 0. 204 mmol/L, which was significantly (P <0.001) higher, by 34%, than in controls. The odds ratio for CHD risk in men with Lp(a)-C >/=0. 259 mmol/L (>/=10 mg/dL), after adjusting for age, HDL-cholesterol, LDL-cholesterol, smoking, diabetes, blood pressure, and body mass index, was 2.293 (confidence interval, 1.55-3.94; P <0.0005). Lp(a)-C values correlated highly with a Lp(a)-mass immunoassay [ApotekTM Lp(a); r = 0.832; P <0.0001; n = 1000].
CONCLUSIONS: An increased Lp(a)-C value >/=0.259 mmol/L (>/=10 mg/dL) is an independent CHD risk factor in men with a relative risk of more than 2, but was inconclusive in women. Lp(a)-C measurements offer an alternative to Lp(a)-mass immunoassays and can be performed on automated analyzers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10388480

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  17 in total

1.  Clinical implications of elevated lipoprotein(a).

Authors:  A von Eckardstein; G Assmann
Journal:  Curr Atheroscler Rep       Date:  2001-07       Impact factor: 5.113

Review 2.  Lipoprotein(a): implications for clinical practice.

Authors:  Robert C Block; Thomas A Pearson
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

Review 3.  Genetics of the Framingham Heart Study population.

Authors:  Diddahally R Govindaraju; L Adrienne Cupples; William B Kannel; Christopher J O'Donnell; Larry D Atwood; Ralph B D'Agostino; Caroline S Fox; Marty Larson; Daniel Levy; Joanne Murabito; Ramachandran S Vasan; Greta Lee Splansky; Philip A Wolf; Emelia J Benjamin
Journal:  Adv Genet       Date:  2008       Impact factor: 1.944

Review 4.  Consensus statement on management of dyslipidemia in Indian subjects.

Authors:  K Sarat Chandra; Manish Bansal; Tiny Nair; S S Iyengar; Rajeev Gupta; Subhash C Manchanda; P P Mohanan; V Dayasagar Rao; C N Manjunath; J P S Sawhney; Nakul Sinha; A K Pancholia; Sundeep Mishra; Ravi R Kasliwal; Saumitra Kumar; Unni Krishnan; Sanjay Kalra; Anoop Misra; Usha Shrivastava; Seema Gulati
Journal:  Indian Heart J       Date:  2014-12-24

5.  Lipoprotein(a) predicts progression of carotid artery intima-media thickening in patients with type 2 diabetes: A four-year follow-up.

Authors:  Jozo Boras; Spomenka Ljubic; Nikica Car; Zeljko Metelko; Mladen Petrovecki; Marijana Vucic Lovrencic; Zeljko Reiner
Journal:  Wien Klin Wochenschr       Date:  2010-03       Impact factor: 1.704

6.  Dimyristoylphosphotidylcholine induces conformational changes in apoB that lowers lipoprotein(a).

Authors:  Yan-Ting Wang; Anne von Zychlinski; Sally P A McCormick
Journal:  J Lipid Res       Date:  2008-12-19       Impact factor: 5.922

Review 7.  Dietary fructose and glucose differentially affect lipid and glucose homeostasis.

Authors:  Ernst J Schaefer; Joi A Gleason; Michael L Dansinger
Journal:  J Nutr       Date:  2009-04-29       Impact factor: 4.798

8.  Lipoprotein(a): biology and clinical importance.

Authors:  Sally P A McCormick
Journal:  Clin Biochem Rev       Date:  2004-02

Review 9.  Rare thrombophilic conditions.

Authors:  Gian Luca Salvagno; Chiara Pavan; Giuseppe Lippi
Journal:  Ann Transl Med       Date:  2018-09

10.  Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis.

Authors:  C A Wijbrandts; S I van Leuven; H D Boom; D M Gerlag; E G S Stroes; J J P Kastelein; P P Tak
Journal:  Ann Rheum Dis       Date:  2008-08-22       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.